FDA
-
-
-
-
-
-
-
RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE TENTATIVE SETTLEMENT OF PENDING LITIGATION
-
-
-
-
-
-
-
Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001
-
-
-
-
-
-
-
Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation
-
-
-
-
-
-
-
NRx Pharmaceuticals (NRXP) Announces Initiation of Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAMI Trial in the Nation of Georgia
-
-
-
-
-
-
-
NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19
-
-
-
-
-
-
-
Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for
-
-
-
-
-
-
-
NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100™ (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critica
-
324,251 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

